GlycoNano™ Carbohydrate Base Material Bioink Production Service
Overview of Bioink in 3D Bioprinting
The objective of 3D bioprinting is to fabricate living volumetric constructs through the sequential deposition of materials harboring living cells, known as bioinks. This bioink is not only central but also the distinctive feature that demarcates "bioprinting" from "3D printing." The efficacy in generating functional tissues is profoundly influenced by the quality of the bioink. The biomaterial ink's composition and the mechanisms of network crosslinking are pivotal in determining the mechanical, physicochemical, and biological properties of the resultant 3D constructs. Natural-origin carbohydrates, such as alginate, gelatin, and hyaluronic acid, have been extensively utilized in 3D bioprinting due to their versatility, biodegradability, biocompatibility, lack of immunogenicity, and, in certain instances, their structural resemblance to the decellularized extracellular matrix (ECM) of native tissues.
Engineering GlycoNano™ Precision: Where Carbohydrate Base Material Meets Bioprinting Excellence
CD BioGlyco is at the forefront of this innovative field and leverages the unique properties of natural-origin carbohydrates to create a bioink that not only meets but exceeds the stringent requirements of 3D bioprinting. Based on the advanced GlycoNano™ Platform, we provide a comprehensive solution that offers a diverse range of bioinks derived from various natural-origin carbohydrates. Each bioink is meticulously designed to cater to specific needs in 3D bioprinting, ensuring optimal performance in terms of printability, mechanical properties, and biological functionality.
- Chitosan base material bioink
- Alginate base material bioink
- Carrageenan base material bioink
- Gellan gum base material bioink
- Methacrylated alginate base material bioink
- Methacrylated hyaluronic acid base material bioink
- Thiolated-hyaluronic acid base material bioink
- Thiolated-hyaluronic acid & gelatin base material bioink
- Thiolated-hyaluronic acid & heparin base material bioink
- Methacrylated dextran base material bioink
- Methacrylated chitosan base material bioink
- Alginate & cellulose base material bioink
- Nanofibrillar cellulose base material bioink
- Alginate & nanofibrillated cellulose base material bioink
- Alginate & gelatin methacryloyl base material bioink
- Alginate & collagen base material bioink
- Alginate & mColMA base material bioink
- Alginate & mColSA base material bioink
The production of carbohydrate base material bioink involves several critical steps, from the synthesis of the carbohydrate base material to the formulation of the bioink and its characterization.
Preparation of Carbohydrate Base Material
We prepare the carbohydrate base material, which serves as the foundational component of the bioink, by dissolving it in a suitable aqueous solution. This solution is stirred overnight at room temperature to ensure complete dissolution. Other bioink components, such as crosslinking agents, stabilizers, and additional structural components, are prepared in their respective forms, either as powders or solutions.
In Vitro Cell Culture
We culture specific cell lines in a medium conducive to cell growth, supplemented with necessary nutrients. The cells are then harvested using enzymatic digestion and centrifugation to obtain a concentrated cell pellet. The cell pellet is resuspended in a serum-free medium and subsequently mixed with other bioink excipients to formulate the bioink.
Formulation of Bioink
The bioink formulation is prepared in separate vials under sterile conditions. Each vial contains different components of the bioink, including the dissolved carbohydrate base material, crosslinking agents, and a mixture of cells and structural components. We mix the carbohydrate base material and crosslinking agents to create a neutral solution, which is then subjected to centrifugation to remove air bubbles. This neutral solution is then combined with the remaining components and homogeneously mixed to obtain the final bioink formulation.
Rheological Characterization
- A rheometer is used to measure the viscosity and yield stress of the bioink. Viscosity is determined by subjecting the bioink to a logarithmic shear rate sweep, while yield stress is measured using an oscillatory shear strain sweep.
- We evaluate the bioink's storage modulus recovery by subjecting it to three phases of oscillatory shearing, including an initial low-strain phase, a high-strain phase to mimic extrusion through a nozzle, and a final low-strain phase to assess recovery.
- The gelling kinetics of the bioink are determined using a dynamic time sweep, where the crossover point of the storage modulus (G′) and loss modulus (G″) is used to determine the gelation time.
Workflow

Publication Data
DOI: 10.3389/fmats.2019.00179
Journal: Biomaterials Research
Published: 2023
IF: 8.1
Result: The authors of this review discuss the use of hyaluronic acid and its derivatives as bioinks in 3D bioprinting for tissue regeneration and biomedical engineering. They cover the modification and cross-linking methods of hyaluronic acid, evaluate the strengths and limitations of these methods, and review the practical clinical applications and outcomes of hyaluronic acid bioinks. The review also identifies the challenges and opportunities in the development of hyaluronic acid bioinks, providing insights and references for future research.
Applications
- Bioinks are used to create 3D structures that mimic the properties of natural tissues, enabling the development of functional tissues for transplantation.
- Bioinks can be used to test the efficacy and toxicity of drugs, providing a more accurate model than traditional 2D cell cultures.
- Bioinks help in the repair and regeneration of damaged tissues and organs by providing scaffolds for cell growth and differentiation.
Advantages
- We offer a variety of bioinks based on natural carbohydrates, including chitosan, alginate, carrageenan, gellan gum, methacrylated alginate, methacrylated hyaluronic acid, thiolated hyaluronic acid, and many more.
- We provide a comprehensive solution that covers the entire process from the synthesis of the carbohydrate base material to the formulation of the bioink and its characterization.
- Our bioinks are versatile and can be customized to meet specific requirements in 3D bioprinting.
Frequently Asked Questions
- Which types of tissues can be 3D printed using our bioinks?
Our bioinks for 3D printing can be designed to create a wide range of tissue types, including but not limited to:- Skin
- Bone
- Cardio
- Hepar
- What are the types of bioprinting technologies?
- Extrusion
- Droplet
- Laser-assisted bioprinting
At CD BioGlyco, our GlycoNano™ Bioink Production Service is poised to revolutionize the way functional tissues are created, offering researchers and clinicians unprecedented control and versatility in their work. If you want to push the boundaries of 3D bioprinting by delivering bioinks that set new standards in precision, reliability, and performance, contact us!
Reference
- Chen, H., et al. 3D printed scaffolds based on hyaluronic acid bioinks for tissue engineering: a review. Biomaterials Research. 2023, 27(1): 137.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





